[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cocaine-use-disorder-cud\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cocaine-use-disorder-cud":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,70,102],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100630663","contingency-management-plus-deep-transcranial-magnetic-stimulation-for-the-treatment-of-cocaine-use-disorder-100630663",false,"NCT07490600","Contingency Management Plus Deep Transcranial Magnetic Stimulation for the Treatment of Cocaine Use Disorder","Contingency Management Plus Deep Transcranial Magnetic Stimulation for the Treatment","Inclusion Criteria:\n\n* Able to provide informed consent before any study-related activity, willing to comply with all study procedures, and be available for the duration of the study.\n* Meet Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) diagnostic criteria for moderate-to-severe CUD and report recent cocaine use (verified by at least one positive urine drug screen (UDS) for the cocaine metabolite benzoylecgonine (BE), during intake).\n* Agree (if the participant is female and of child-bearing potential) to use effective contraceptive methods, unless the participant's male partner(s) is surgically sterile (underwent vasectomy).\n\nAcceptable contraceptives include:\n\n1. oral contraceptives\n2. contraceptive sponge\n3. patch\n4. double barrier (diaphragm\u002Fspermicidal or condom\u002Fspermicidal)\n5. intrauterine contraceptive system\n6. etonogestrel implant\n7. medroxyprogesterone acetate contraceptive injection\n8. complete abstinence from sexual intercourse\n9. hormonal vaginal ring\n\nContraceptive measures sold for emergency use after unprotected sex are not acceptable methods for routine use.\n\n* Women of child-bearing potential must provide negative urine pregnancy test prior to randomization.\n* Be able to provide the names and contact information of at least 2 persons who can consistently locate their whereabouts\n\nExclusion Criteria:\n\n* Current DSM-5 diagnosis for substance use disorder (of at least moderate severity) other than cocaine, cannabis, or nicotine or a substance Use Disorder (SUD) requiring medical detoxification (e.g., alcohol, opioid, benzodiazepine)\n* Presence of any medical, neurological, psychiatric, or physical condition, disease, or illness (including psychosis and bipolar disorder) that, in the opinion of the PIs and the Certified Registered Nurse Anesthetist (CNRA)Medical Director could: (a) compromise interfere, limit, or reduce the subject's ability to complete the study; or (b) adversely impact the safety of the subject or the integrity of the data.\n* Has current or recent (within 3 months of potential enrollment) suicidal ideation, suicidal behavior, homicidal ideation or a homicidal plan sufficient to raise subject safety concerns based on the following assessments:\n\n  1. Structured Clinical Interview for DSM-5 (SCID-5)\n  2. Columbia-Suicide Severity Rating Scale - Answers YES to Questions 3, 4, 5, or 6\n  3. Assault \\& Homicidal Danger Assessment Tool - Key to Danger \\> 1\n* Any contraindications to MRI scans (metal in the body; claustrophobia). -Medical implants contraindicating TMS (i.e., aneurysm clips or coils, stents, implanted stimulators, implanted vagus nerve or deep brain stimulators, implanted electrical devices such as pacemakers or medication pumps, electrodes for monitoring brain activity, cochlear implants for hearing, any magnetic implants, bullet fragments, any other metal device or object implanted in your body closer than 30 cm from the coil).\n* History of brain surgery.\n* History of an intracranial lesion or any medical or neurological diagnosis\u002Fcondition associated with increased intracranial pressure (i.e., Idiopathic Intracranial Hypertension\u002FPseudotumor Cerebri) OR any of the following symptoms within 30 days of enrollment: headaches \\> 15 days\u002Fmonth, loss of vision or decreased vision\n* Moderate-to-severe heart disease.\n* History of stroke.\n* Taking any antidepressant or antipsychotic medication at a dose above the maximum recommended dose or at a dose deemed to be potentially unsafe according to the study physician; has taken any of the following medications, which are known to increase the risk of seizures, within 1 week of study enrollment; or does not agree to abstain from taking the following medications during study participation:\n\n  1. clozapine\n  2. chlorpromazine\n  3. bupropion\n  4. clomipramine hydrochloride\n  5. amoxapine\n  6. maprotiline hydrochloride\n  7. diphenhydramine\n  8. stimulants other than cocaine including the following:\n  9. Dextroamphetamine and amphetamine ii. Dextroamphetamine iii. Lisdexamfetamine dimesylate iv. Methamphetamine\n\n  v. Methylphenidate i. tramadol j. isoniazid.\n* Personal history of epilepsy or seizure disorder and\u002For family history including a first degree relative\n* Serious head injury with loss of consciousness\n* Having conditions of probation or parole requiring reports of drug use to officers of the court or impending incarceration\n* For adolescent aged participants (18-21 only): any risk factor for neurocardiogenic syncope (history of syncope\u002F presyncope related to noxious stimuli, anxiety, micturition, or posture).\n* Pregnant or nursing for female participants\n* Inability to read, write, or speak English.",true,"ALL","18 Years","65 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this study is to evaluate the effects of Contingency Management (CM)+transcranial magnetic stimulation (TMS) on treatment outcomes in individuals who are initial non-responders and to evaluate the effects of CM+TMS on putative mechanisms of change",[28],"Cocaine Use Disorder (CUD)",[30,31,32],"Cocaine treatment","Cocaine","Crack","RECRUITING","2026-06-22",{"date":36,"type":37},"2026-06-25","ACTUAL",{"date":39,"type":37},"2026-04-21",{"date":41,"type":22},"2029-09-01",{"name":43,"class":44},"The University of Texas Health Science Center, Houston","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":45},"100638136","phase-1-the-impact-of-cobenfy-maintenance-on-cocaines-effects-100638136","NCT07624227","The Impact of Cobenfy Maintenance on Cocaine's Effects","Inclusion Criteria:\n\n* Must meet criteria for cocaine use disorder - report past month smoked or IV cocaine use, and provide a urine sample positive for recent cocaine use during screening.\n* Female subjects of childbearing potential must be using an effective form of birth control (e.g., birth control pills, surgical sterilization, IUD, cervical cap with a spermicide, or abstinence). Exceptions include women reporting 12 months of spontaneous amenorrhea, 6 months of spontaneous amenorrhea with a follicle stimulating hormone (FSH) level \\> 40 mIU\u002FmL, or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy. Urine pregnancy tests will be conducted prior to sessions to ensure that female subjects do not participate if pregnant.\n* Able to speak and read English.\n\nExclusion Criteria:\n\n* Chemistry values or screening outcomes including outside normal ranges that are deemed by the study physician to be clinically significant. Lipid levels are also included in this protocol as an additional check for cardiovascular health.\n* Persistent hypertension \\>140\u002F90 mmHg or tachycardia \\>100 bpm for three consecutive recordings during screening.\n* AST, ALT or alkaline phosphatase \\>3x ULN.\n* Creatinine levels \\>1.2x ULN will be repeated; subjects with creatinine re-test values remaining above this level will be excluded.\n* Bilirubin levels \\>1.5x ULN will be repeated to determine trends; subjects with bilirubin increasing over time will be excluded.\n* Subjects presenting with anemia (hematocrit \\\u003C 36) or evidence of current infection (white blood cell count \\> 5) are referred to their PCP. If urine protein is greater than trace, urinalysis is repeated, and subjects with continued elevation is referred to their PCP. Subjects can be reconsidered for enrollment if these issues are resolved.\n* Electrocardiogram abnormalities, including:\n* Atrial premature beats (\\>= 2 consecutive)\n* Ventricular premature beats (Lown's Grade 3 or higher; \\>= 2 consecutive beats, multiform)\n* Heart block (2nd or 3rd degree AV block or bundle branch block)\n* Pre-excitation syndromes (Wolff-Parkinson-White or Lown-Ganong-Levine)\n* QTc interval \\> 450 msec\n* History of serious physical disease, current physical disease, impaired cardiovascular functioning, chronic obstructive pulmonary disease, history of head trauma with prolonged loss of consciousness, seizures or CNS tumors, or current or past histories of serious psychiatric disorder that in the opinion of the study physician would interfere with study participation.\n* First degree family member with significant premature cardiac comorbidity.\n* Contraindications for Cobenfy not covered by other exclusion criteria including urinary retention, moderate\u002Fsevere hepatic impairment, gastric retention and untreated narrow-angle glaucoma.\n* Meet diagnostic criteria for psychoactive substance use disorder for substances other than cocaine or nicotine\u002Fcaffeine that would require detoxification (i.e., alcohol, opioids, benzodiazepines or barbiturates). Negative urine\u002Fbreath samples for these substances, and the absence of withdrawal, will be required during screening.\n* Regular use of other medications, with the exception of hormone-based contraceptives for female subjects, daily multivitamins, short-term antibiotic prescriptions, and\u002For antiretrovirals for the hepatitis C virus.\n* Vision or hearing problems that would preclude completion of experimental tasks.\n* Poor venous access.\n* Seeking treatment for SUD.","60 Years",{"count":54,"type":22},32,[56,57],"PHASE1","PHASE2","The goal of this clinical trial is to learn if Cobenfy influences the effects of cocaine in people with cocaine use disorder. This trial will also provide information about the safety and tolerability of combining Cobenfy and cocaine.\n\nResearchers will compare Cobenfy to a placebo (a look-alike substance that contains no drug) to see if Cobenfy is a safe, tolerable and effective at blocking cocaine's effects in participants with cocaine use disorder.\n\nParticipants will:\n\n* Participate in an 11-day inpatient trial\n* Take Cobenfy or placebo twice per day.\n* Participate in experimental sessions to test the effects of Cobenfy (or placebo) on the response to cocaine and cocaine self-administration.",[28],"NOT_YET_RECRUITING","2026-05-28",{"date":63,"type":37},"2026-06-03",{"date":65,"type":22},"2026-08-01",{"date":67,"type":22},"2032-06-30",{"name":69,"class":44},"Joshua A. Lile, Ph.D.",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":45},"100633882","the-role-of-potassium-channels-in-working-memory-impairments-of-chronic-cocaine-users-100633882","NCT07532460","The Role of Potassium Channels in Working Memory Impairments of Chronic Cocaine Users","Randomised, Double-Blind, Placebo-Controlled, Crossover Study Investigating the Role of Potassium Channels in Working Memory Impairments of Chronic Cocaine Users","POTCHICUD","Inclusion Criteria:\n\n* Current diagnosis of mild, moderate, or severe CoUD according to DSM-5\n* Minimum cocaine use of 1g\u002Fmonth in the last three months\n* Cocaine as the primary drug of consumption\n* Willingness to abstain from cocaine use at least 72 hours before prior to each study visit\n* Ability to read, understand and provide written informed consent\n* To be sufficiently fluent in German\n* Age between 20 and 50 years\n* Body mass index (BMI) between 19 and 30 kg\u002Fm2\n* If applicable: luteal phase of the menstrual cycle\n* For individuals with childbearing potential: use of contraceptive measures\n\nExclusion Criteria:\n\n* Presence or history of severe neurological disorders or head injuries\n* Current diagnosis of an acute or chronic infectious disease\n* If applicable: pregnancy and breastfeeding\n* Lifetime history of any epileptic seizures\n* Lifetime diagnosis of a cardiovascular disease, specifically arrhythmia and long QT syndrome\n* Clinically significant laboratory or ECG abnormality that could be a safety issue in the study\n* Lifetime diagnosis of liver or kidney disease including moderate or severe renal impairment (creatinine clearance \\\u003C 50 ml\u002Fmin)\n* Known hypersensitivity or allergy to 4-aminopyridine\n* Use of potassium channel blockers within the last 3 months\n* Use of psychotropic medication within the last 7 days\n* Use of inhibitors of the organic cation transporter 2 (OCT2), such as cimetidine\n* Lifetime diagnosis of schizophrenia, bipolar disorder, obsessive-compulsive disorder, or autism spectrum disorder according to DSM-5\n* Diagnosis of a current episode of depression\n* Current diagnosis of a moderate or severe substance use disorder other than CoUD according than DSM-5\n* Daily cannabis consumption in the past three months\n* (E-Cigarette) Fagerström Test of Nicotine Dependence Score \\> 5 (strong nicotine dependence)\n* Inability to follow the procedures of the study, e.g., due to language problems\n* Being related to or in any form dependent on the investigator\n* Prior participation (less than two years ago) in a study investigating working memory using the n-back task, the SWM, PAL, RVP, or LNST\n* Participation in another study with investigational drugs within the 30 days preceding and during the present study","20 Years","50 Years",{"count":81,"type":22},40,[25],"The study aims to address the neurobiological basis of cognitive impairments in chronic cocaine users by investigating the potential impact of an acute potassium channel blockade on working memory performance and other cognitive functions.",[28,85],"Cognitive Impairments",[87,88,89,90,91,92],"cognitive impairments","cocaine use disorder","potassium channels","working memory","4-aminopyridine","fampridine","2026-04-15",{"date":95,"type":37},"2026-04-20",{"date":97,"type":22},"2026-04",{"date":99,"type":22},"2027-08",{"name":101,"class":44},"Boris Quednow",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":114,"briefSummary":115,"conditions":116,"keywords":119,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":45},"100598460","web-based-alcohol--or-cocaine-specific-inhibition-training-in-adolescents-and-young-adults-with-substance-use-disorder-100598460","NCT07071779","Web-based Alcohol- or Cocaine-specific Inhibition Training in Adolescents and Young Adults With Substance Use Disorder","Web-based Alcohol- or Cocaine Specific Inhibition Training in Adolescents and Young Adults With Substance Use Disorder","WAIT-AYA","Inclusion Criteria:\n\n* Age 14 - 35 years\n* Alcohol use disorder identification test (AUDIT) ≥ 7 or Drug Use Identification Test (DUDIT) ≥ 8\n* Currently undergoing outpatient treatment or online counselling in one of 7 specialized treatment settings\n* Sufficient German language skills\n* Informed Consent as documented by signature\n* Owner of a smartphone with internet access\n\nExclusion Criteria:\n\n* Other severe substance use (except nicotine and cannabis) determined by the cut-off value ≥ 25 in the drug use disorder identification test (DUDIT)\n* Current medical conditions excluding participation\n* Inability to read and understand the participant's information\n* Enrolment of the investigator, his\u002Fher family members, employees, and other dependent persons\n\nAdditional exclusion criteria for Electroencephalography (EEG)-substudy:\n\n* Current medication affecting EEG (e.g., benzodiazepines)\n* Other severe substance use determined by the cut-off value ≥ 25 in the DUDIT (except nicotine)\n* History of epilepsy\n* Cochlea implant","14 Years","35 Years",{"count":113,"type":22},210,[25],"Substance misuse is one of the most common risk factors for health problems and premature death among adolescents and young adults worldwide. Although there are effective treatments for substance use disorder (SUD), there is still a need to further improve their effectiveness and make them easier to access. Early research suggests that substance-specific inhibition training, when used in addition to specialized treatment, can improve treatment outcomes. This training aims to strengthen inhibition specifically in situations with substance-related cues. The goal of this project is to offer this training for the first time in the form of a smartphone app, which is expected to increase the availability of the training. The main aim of the study is to evaluate whether this new app-based cognitive training is feasible as an add-on to the treatment of SUD in adolescents and young adults. In addition, the study will gather preliminary insights into whether the training affects drinking behavior and related brain processes. The project will be conducted as a double-blind, clinical pilot study. A total of 210 adolescents and young adults between 14 and 35 years old will be recruited from five specialized treatment centers. After the first study visit, participants will be randomly assigned to one of two groups: (1) an intervention group receiving the alcohol-specific inhibition training or (2) a control group receiving a similar alcohol-nonspecific inhibition training. During their participation, all participants will complete six short training sessions with the app. About one month later, they will complete six additional booster training sessions. This research may help develop effective, easily accessible tools to support young people with substance use disorder.",[117,28,118],"Alcohol Use Disorder (AUD)","Substance Use Disorder (SUD)",[120,121,122,123,28,118,124,125],"Alcohol use disorder","Alcohol-specific inhibition training","Cognitive bias modification","Feasibility pilot randomized controlled trial","Cocaine-specific inhibition training","Substance-specific inhibition training","2026-02-16",{"date":128,"type":37},"2026-02-18",{"date":130,"type":37},"2025-07-23",{"date":132,"type":22},"2026-08",{"name":134,"class":44},"University of Bern"]